CVS HEALTH CORPORATION (CVS) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy bene...
CVS HEALTH CORPORATION (CVS) currently trades at a P/E ratio of 24.16 (historical range: 9.28–227.29, median: 17.60), placing it at the 65th percentile — above its historical average, P/S ratio of 0.28 (range: 0.15–0.52, 58th percentile — near its historical average), EV/EBITDA of 13.22 (range: 9.17–31.84, 38th percentile).
Over the historical period (2021-09-14 to 2026-10-16), CVS HEALTH CORPORATION's P/E ratio has expanded by 158% over the observed period (from an average of 21.8 to 56.3).
CVS HEALTH CORPORATION trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 24.16 | 17.60 | 65th | above its historical average |
| P/S Ratio | 0.28 | 0.27 | 58th | near its historical average |
| EV/EBITDA | 13.22 | 13.83 | 38th | below its historical average |
| FCF Yield | 9.95% | 10.71% | 45th | near its historical average |
CVS HEALTH CORPORATION (CVS) Valuation & P/E History
CVS HEALTH CORPORATION (CVS) is a US-listed stock operating in the Healthcare sector, specifically the Healthcare Plans industry currently trading at $92.37 with a market capitalization of $118.1 billion. This page provides historical valuation analysis for CVS based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 24.16 is above the historical median of 17.60, placing CVS at the 65th percentile of its valuation range. The P/S ratio of 0.28 compares to a median of 0.27.
CVS Valuation Metrics & Historical Range
The valuation table above shows CVS HEALTH CORPORATION's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether CVS is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests CVS is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for CVS HEALTH CORPORATION.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is CVS Overvalued or Undervalued?
CVS HEALTH CORPORATION trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 54 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive CVS is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full CVS analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.CVS trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.